Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for cognitive impairment after ECT in major depressive disorder
IRCT201506203930N38Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of memantine in major depressive disorder (MDD) and cognitive disorder (CD), sponsored by Shiraz University of Medical Sciences. Started May 2016; status: completed.
02
Drugs
memantine
03
Conditions
major depressive disorder (MDD)cognitive disorder (CD)
Beyond the preview
Go deeper on IRCT201506203930N38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201506203930N38.